Prestige Consumer Healthcare (NYSE:PBH) was upgraded by investment analysts at Sidoti from a “neutral” rating to a “buy” rating in a research report issued on Monday, Marketbeat.com reports. The brokerage currently has a $46.00 price objective on the stock. Sidoti’s price target indicates a potential upside of 22.47% from the company’s current price.
PBH has been the topic of a number of other reports. TheStreet upgraded Prestige Consumer Healthcare from a “c” rating to a “b-” rating in a report on Thursday, May 7th. BMO Capital Markets lifted their target price on Prestige Consumer Healthcare from $85.00 to $91.00 and gave the stock a “market perform” rating in a report on Tuesday, May 12th. Jefferies Financial Group cut Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Tuesday, April 14th. ValuEngine cut Prestige Consumer Healthcare from a “hold” rating to a “sell” rating in a report on Friday, May 1st. Finally, CIBC lifted their target price on Prestige Consumer Healthcare from $86.00 to $88.00 and gave the stock a “neutral” rating in a report on Tuesday, May 12th. One analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $63.29.
PBH opened at $37.56 on Monday. Prestige Consumer Healthcare has a one year low of $27.40 and a one year high of $46.12. The company has a debt-to-equity ratio of 1.50, a quick ratio of 1.67 and a current ratio of 2.44. The stock’s fifty day moving average is $40.55 and its 200-day moving average is $39.59. The company has a market capitalization of $1.85 billion, a PE ratio of 13.51, a P/E/G ratio of 3.08 and a beta of 0.80.
Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.82 EPS for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.08. Prestige Consumer Healthcare had a return on equity of 13.33% and a net margin of 14.77%. The company had revenue of $251.20 million for the quarter, compared to the consensus estimate of $239.65 million. During the same quarter in the previous year, the business earned $0.72 EPS. The company’s quarterly revenue was up 4.2% compared to the same quarter last year. On average, equities research analysts forecast that Prestige Consumer Healthcare will post 2.99 EPS for the current fiscal year.
In related news, CEO Ronald M. Lombardi sold 29,593 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $40.00, for a total transaction of $1,183,720.00. Following the completion of the sale, the chief executive officer now owns 154,630 shares of the company’s stock, valued at $6,185,200. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.14% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in PBH. Victory Capital Management Inc. boosted its position in Prestige Consumer Healthcare by 31.0% during the fourth quarter. Victory Capital Management Inc. now owns 36,392 shares of the company’s stock valued at $1,474,000 after purchasing an additional 8,604 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Prestige Consumer Healthcare by 3.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 508,789 shares of the company’s stock worth $20,606,000 after buying an additional 19,311 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of Prestige Consumer Healthcare during the 4th quarter worth about $122,000. Bank of Montreal Can lifted its position in shares of Prestige Consumer Healthcare by 57.5% during the 4th quarter. Bank of Montreal Can now owns 13,827 shares of the company’s stock worth $560,000 after purchasing an additional 5,047 shares during the last quarter. Finally, Barclays PLC lifted its position in shares of Prestige Consumer Healthcare by 77.1% during the 4th quarter. Barclays PLC now owns 89,660 shares of the company’s stock worth $3,631,000 after purchasing an additional 39,027 shares during the last quarter.
About Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare and household cleaning products in North America, Australia, and internationally. It operates in three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning.
Featured Story: Sell-Side Analysts
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.